KPTI

Insider Trades

Name	Value	Action	Price	Last Price
Abate KristinChief Accounting Officer $50453 shares SellMay 14, 2026 $9.50 $9.11
Cheng Sohanya RoshanEVP & Chief Commercial Officer $3.1k324 shares SellMay 14, 2026 $9.50 $9.11
Mano MichaelEVP, CLO&Secretary $2.5k266 shares SellMay 14, 2026 $9.50 $9.11
Poulton StuartEVP, Chief Development Officer $3.8k403 shares SellMay 14, 2026 $9.50 $9.11
Rangwala ReshmaEVP & Chief Medical Officer $3.9k408 shares SellMay 14, 2026 $9.50 $9.11
Paulson Richard A.Director, Officer: President And CEO $21k2.2k shares SellMay 14, 2026 $9.50 $9.11

News

prnewswire.comKaryopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026prnewswire.comJun 3

seekingalpha.comKaryopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcriptseekingalpha.comJun 3

gurufocus.comKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026gurufocus.comJun 2

prnewswire.comKaryopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026prnewswire.comJun 2

prnewswire.comKaryopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncologyprnewswire.comJun 2

Trade KPTI

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

CEO: Richard A. Paulson
IPO Date: Nov 6, 2013

Market Data

Open: $9.60
High: $9.74
Low: $8.90
Volume: 491.9K
Avg Volume: 839.9K
52W High: $10.99
52W Low: $3.65

Valuation

Market Cap: $204M
Enterprise Value: $344M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-75M
Revenue: $146M
Net Income: $-196M
Cash: $61M
Debt: $234M

Events

EarningsAug 10

EPS est. -1.31